KLTO
Klotho Neurosciences, Inc.
Biotechnology
Market Cap$7M
5Y Perf.-59.1%
Build Your Comparison
Side-by-side financial analysisKLTO
ACIU
Try popular comparisons:
Stock Comparison
KLTO vs ACIU
Revenue, margins, valuation, and 5-year total return — side by side.
ACIU
AC Immune S.A.
Biotechnology
Market Cap$235M
5Y Perf.-9.3%
KLTO vs ACIU — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  KLTO |  ACIU |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $7M | $235M |
| Revenue (TTM) | $0.00 | $4M |
| Net Income (TTM) | $-11M | $-70M |
| Gross Margin | — | 100.0% |
| Operating Margin | — | -19.3% |
| Total Debt | $272K | $5M |
| Cash & Equiv. | $64K | $27M |
KLTO vs ACIU — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KLTO
ACIU
| Stock | Aug 24 | Mar 26 | Return |
|---|---|---|---|
| Klotho Neuroscience… (KLTO) | 100 | 40.9 | -59.1% |
| AC Immune S.A. (ACIU) | 100 | 90.7 | -9.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KLTO vs ACIU
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACIU leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Klotho Neurosciences, Inc. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ACIU emerged as the overall leader. Track its performance:
KLTO
Klotho Neurosciences, Inc.
The Long-Run Compounder
KLTO is the clearest fit if your priority is long-term compounding.
- -63.0% 10Y total return vs ACIU's -85.2%
- -14.5% margin vs ACIU's -19.7%
Best for: long-term compounding
ACIU
AC Immune S.A.
The Income Pick
ACIU carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.69
- Rev growth -86.9%, EPS growth -37.3%, 3Y rev CAGR -3.2%
- Lower volatility, beta 1.69, Low D/E 10.1%, current ratio 1.02x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ACIU | -86.9% revenue growth vs KLTO's -49.0% |
| Quality / Margins |  KLTO | -14.5% margin vs ACIU's -19.7% |
| Stability / Safety | ACIU | Beta 1.69 vs KLTO's 1.91, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ACIU | +11.6% vs KLTO's -81.0% |
| Efficiency (ROA) | ACIU | -38.7% ROA vs KLTO's -112.1%, ROIC -99.2% vs -242.3% |
KLTO vs ACIU — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACIULAGGINGKLTO
KLTOKlotho Neurosciences,…
1leads
ACIUAC Immune S.A.
3leads
6 Total Categories
CATEGORYLEADERvs KLTOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KLTO1/1
Valuation MetricsMultiples, price ratios, and targets
ACIU2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACIU6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
ACIU2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KLTO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ACIU and KLTO operate at a comparable scale, with $4M and $0 in trailing revenue.
| Metric | KLTOKlotho Neuroscien… | ACIUAC Immune S.A. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $4M |
| EBITDAEarnings before interest/tax | -$8M | -$67M |
| Net IncomeAfter-tax profit | -$11M | -$70M |
| Free Cash FlowCash after capex | -$6M | -$70M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | -19.3% |
| Net MarginNet income ÷ Revenue | — | -19.7% |
| FCF MarginFCF ÷ Revenue | — | -19.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -70.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +72.9% | +6.7% |
KLTO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ACIU leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | KLTOKlotho Neuroscien… | ACIUAC Immune S.A. |
|---|---|---|
| Market CapShares × price | $7M | $235M |
| Enterprise ValueMkt cap + debt − cash | $8M | $207M |
| Trailing P/EPrice ÷ TTM EPS | -1.19x | -2.63x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 52.43x |
| Price / BookPrice ÷ Book value/share | 6.19x | 4.13x |
| Price / FCFMarket cap ÷ FCF | — | — |
ACIU leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ACIU leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ACIU delivers a -101.6% return on equity — every $100 of shareholder capital generates $-102 in annual profit, vs $-114 for KLTO. ACIU carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to KLTO's 0.23x. On the Piotroski fundamental quality scale (0–9), KLTO scores 4/9 vs ACIU's 2/9, reflecting mixed financial health.
| Metric | KLTOKlotho Neuroscien… | ACIUAC Immune S.A. |
|---|---|---|
| ROE (TTM)Return on equity | -113.7% | -101.6% |
| ROA (TTM)Return on assets | -112.1% | -38.7% |
| ROICReturn on invested capital | -2.4% | -99.2% |
| ROCEReturn on capital employed | -6.2% | -72.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.23x | 0.10x |
| Net DebtTotal debt minus cash | $208,012 | -$22M |
| Cash & Equiv.Liquid assets | $63,741 | $27M |
| Total DebtShort + long-term debt | $271,753 | $5M |
| Interest CoverageEBIT ÷ Interest expense | -1.98x | -482.85x |
ACIU leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — KLTO and ACIU each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KLTO five years ago would be worth $3,699 today (with dividends reinvested), compared to $3,117 for ACIU. Over the past 12 months, ACIU leads with a +11.6% total return vs KLTO's -81.0%. The 3-year compound annual growth rate (CAGR) favors ACIU at 2.7% vs KLTO's -28.2% — a key indicator of consistent wealth creation.
| Metric | KLTOKlotho Neuroscien… | ACIUAC Immune S.A. |
|---|---|---|
| YTD ReturnYear-to-date | +19.1% | -31.3% |
| 1-Year ReturnPast 12 months | -81.0% | +11.6% |
| 3-Year ReturnCumulative with dividends | -63.0% | +8.5% |
| 5-Year ReturnCumulative with dividends | -63.0% | -68.8% |
| 10-Year ReturnCumulative with dividends | -63.0% | -85.2% |
| CAGR (3Y)Annualised 3-year return | -28.2% | +2.7% |
Evenly matched — KLTO and ACIU each lead in 3 of 6 comparable metrics.
Risk & Volatility
ACIU leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ACIU is the less volatile stock with a 1.69 beta — it tends to amplify market swings less than KLTO's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACIU currently trades 57.8% from its 52-week high vs KLTO's 15.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KLTOKlotho Neuroscien… | ACIUAC Immune S.A. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 1.69x |
| 52-Week HighHighest price in past year | $2.45 | $4.00 |
| 52-Week LowLowest price in past year | $0.21 | $1.65 |
| % of 52W HighCurrent price vs 52-week peak | +15.6% | +57.8% |
| RSI (14)Momentum oscillator 0–100 | 61.9 | 34.7 |
| Avg Volume (50D)Average daily shares traded | 95K | 294K |
ACIU leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | KLTOKlotho Neuroscien… | ACIUAC Immune S.A. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $7.00 |
| # AnalystsCovering analysts | — | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.6% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACIU leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). KLTO leads in 1 (Income & Cash Flow). 1 tied.
Best OverallAC Immune S.A. (ACIU)Leads 3 of 6 categories
Loading custom metrics...
KLTO vs ACIU: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is KLTO or ACIU a better buy right now?
Analysts rate AC Immune S.
A. (ACIU) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KLTO or ACIU?
Over the past 5 years, Klotho Neurosciences, Inc.
(KLTO) delivered a total return of -63. 0%, compared to -68. 8% for AC Immune S. A. (ACIU). Over 10 years, the gap is even starker: KLTO returned -63. 0% versus ACIU's -85. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KLTO or ACIU?
By beta (market sensitivity over 5 years), AC Immune S.
A. (ACIU) is the lower-risk stock at 1. 69β versus Klotho Neurosciences, Inc. 's 1. 91β — meaning KLTO is approximately 13% more volatile than ACIU relative to the S&P 500. On balance sheet safety, AC Immune S. A. (ACIU) carries a lower debt/equity ratio of 10% versus 23% for Klotho Neurosciences, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — KLTO or ACIU?
Klotho Neurosciences, Inc.
(KLTO) is the more profitable company, earning 0. 0% net margin versus -1971. 6% for AC Immune S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KLTO leads at 0. 0% versus -1927. 3% for ACIU. At the gross margin level — before operating expenses — ACIU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — KLTO or ACIU?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is KLTO or ACIU better for a retirement portfolio?
For long-horizon retirement investors, AC Immune S.
A. (ACIU) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Klotho Neurosciences, Inc. (KLTO) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACIU: -85. 2%, KLTO: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between KLTO and ACIU?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.